Bullish Article Echoes Optimism, But DeepValue Report Urges Caution on UAMY's Execution Risks

What happened

On March 22, 2026, Seeking Alpha published a bullish article rating United States Antimony Corp (UAMY) as a buy, citing national security tailwinds, a $125 million revenue guidance for 2026, and catalysts like the Alaska claim ramp and a tungsten resource. This article reinforces the crowded market narrative around UAMY as a critical minerals play with government contract support. However, the DeepValue master report from March 19, 2026, maintains a 'WAIT' rating, highlighting that UAMY's valuation hinges on unproven execution milestones rather than current earnings. Key risks include the Thompson Falls expansion needing completion by early April 2026 to achieve 400-500 tons/month capacity, the absence of recurring DLA delivery orders beyond an initial $9.95M ceiling, and past equity dilution raising per-share value concerns. The report stresses that without tangible proof of shipments and orders in the next 3-6 months, the stock remains speculative and vulnerable to downside.

Implication

The Seeking Alpha article adds to positive sentiment but overlooks the execution risks detailed in the DeepValue report, such as feedstock economics and contract opacity. UAMY's ability to meet its $125 million revenue guidance depends entirely on successful Thompson Falls commissioning and sustained DLA procurement, which are not yet evidenced. Past dilution from $109.5 million in equity issuance in 2025 heightens sensitivity to any renewed financing, potentially eroding per-share value even if revenue grows. Without visible delivery orders or shipment data, the stock's valuation at a $1.09 billion market cap discounts future success that may not materialize, increasing volatility. A prudent approach is to wait for objective proof points in filings by mid-2026, as failure could trigger a reversion to lower valuation anchors like the bear scenario's $5.00 per share.

Thesis delta

The Seeking Alpha article does not shift the fundamental investment thesis from the DeepValue report, as it repeats promotional points without addressing core risks like execution transparency or dilution history. Any thesis adjustment remains contingent on observable milestones: Thompson Falls ramp-up and new DLA orders by mid-2026, which would validate the bullish narrative or confirm downside risks.